Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics, Inc. reports developments for a clinical-stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases. Its recurring updates center on abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody evaluated in hidradenitis suppurativa, including LOTUS trial results, safety and efficacy disclosures, and program development plans.
Company news also covers financial results, investor presentations and conferences, equity compensation grants, public financing activity involving common stock and pre-funded warrants, and milestone obligations tied to the AlmataBio acquisition. These updates connect Avalo's clinical pipeline, capital needs, and governance actions to its public-company reporting cycle.
Avalo Therapeutics (Nasdaq: AVTX), a clinical stage biotech company focused on IL-1β-based treatments, has appointed Kevin R. Lind to its Board of Directors. Lind brings over 20 years of leadership experience in capital markets and business development, most notably leading Longboard Pharmaceuticals to a $2.6 billion acquisition by H. Lundbeck A/S in 2024.
The appointment comes as Avalo advances AVTX-009 through Phase 2 LOTUS trial in hidradenitis suppurativa (HS), with topline data expected mid-2026. Throughout his career, Lind has raised over a billion dollars for biotech companies and held key positions at Arena Pharmaceuticals, TPG, and Lehman Brothers.
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (September 3), the H.C. Wainwright Global Investment Conference (September 9), and the Stifel Virtual Immunology and Inflammation Forum (September 15). All presentations will be available via webcast on the company's investor relations website, with replays accessible for at least 30 days.
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech company focused on IL-1β-based treatments, reported Q2 2025 financial results and business updates. The company's Phase 2 LOTUS trial for hidradenitis suppurativa (HS) has enrolled over 75% of planned patients, with topline data expected mid-2026.
Financial highlights include $113.3 million in cash and short-term investments as of June 30, 2025, providing runway into 2028. Q2 2025 showed a net loss of $20.8 million ($1.92 per share), compared to net income of $98.5 million in Q2 2024. R&D expenses increased by $9.5 million to $14.1 million, primarily due to LOTUS trial costs.
The company strengthened its leadership by appointing Rita Jain, M.D. to the Board of Directors, bringing valuable experience in clinical development and regulatory strategy.
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company specializing in immune dysregulation treatments, has announced its participation in two upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 7:35 am ET in New York. Additionally, management will join a panel discussion titled "Dermatology: AA, HS, PSO" at the Oppenheimer Innovators in I&I Summit on June 25, 2025, at 10am ET in New York. Webcasts and replays will be available on the company's investor relations website for at least 30 days.
Avalo Therapeutics (NASDAQ: AVTX) reported its Q1 2025 financial results and business updates. The company ended Q1 with $125 million in cash, providing runway into 2027 with potential extension into 2028. The Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa (HS) is progressing as planned, with topline data expected in 2026.
Q1 2025 financial highlights include: net loss of $13.1 million ($1.25 per share), R&D expenses of $9.1 million (up $7.0M YoY), and G&A expenses of $5.5 million (up $2.4M YoY). The company is carefully evaluating the timing of additional development activities beyond LOTUS trial due to current market conditions.
Avalo Therapeutics, a clinical stage biotech company specializing in immune dysregulation treatments, has announced its upcoming participation in the Citizens Life Sciences Conference.
The company's CEO, Dr. Garry Neil, is scheduled to present at the conference on Thursday, May 8, 2025, at 3:00 pm ET in New York. The presentation will be accessible through live webcasts and replays from the company's website.
Investors and interested parties can access the presentation through:
- The "News / Events" section of Avalo's investor relations website at ir.avalotx.com
- Archived webcast replays available for a minimum of 30 days
Avalo Therapeutics (AVTX) has appointed Michael Heffernan as Chairman of the Board of Directors, succeeding Dr. Garry Neil, who will continue as Board member and CEO. The separation of Chairman and CEO roles comes as the company advances its pipeline of targeted therapies for immune-mediated diseases.
The company's lead candidate, AVTX-009, is currently in Phase 2 LOTUS trial for hidradenitis suppurativa (HS), with data readout expected next year. Heffernan brings extensive experience in building biopharmaceutical companies and executing successful exits, positioning him to help guide Avalo's growth strategy and potential indication expansion.
Avalo Therapeutics (NASDAQ: AVTX) reported its 2024 financial results and business updates. The company ended 2024 with $134.5 million in cash, supported by a $185 million private placement, providing runway into at least 2027.
Key financial metrics include:
- Net loss of $35.1 million in 2024, up from $31.5 million in 2023
- R&D expenses increased to $24.4 million
- G&A expenses rose to $17.2 million
- Basic net loss per share was $7.94
The company's Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa (HS) is ongoing, with topline data expected in 2026. The trial will evaluate approximately 180 adults with HS. Jennifer Riley joined as Chief Strategy Officer effective January 2025 to guide strategy and pipeline planning.